Related Experiment Video
Updated: Aug 24, 2026

Murine Intrapulmonary Tracheal Transplantation: A Model for Investigating Obliterative Airway Disease After Lung Transplantation
Published on: November 10, 2023
Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation
Geert M Verleden1, Lieven J Dupont
1University Hospital Gasthuisberg, Department of Respiratory Medicine and Lung Transplantation Unit, Leuven, Belgium. geert.verleden@uz.kuleuven.ac.be
Background:
Bronchiolitis obliterans syndrome (BOS) is the leading cause of late mortality after lung transplantation.
Methods:
We added azithromycin (AZI) (250 mg/day for 5 days, followed by 250 mg every other day) to the current immunosuppressive therapy in eight lung transplant recipients (mean age 36 years) with established BOS in an attempt to prevent further decline of the forced expiratory volume in 1 sec (FEV1).
Results:
Before the administration of AZI, there was a gradual decline of the FEV1 (-34.4%+/-14.7%) compared with the patients' best postoperative values. Twelve weeks after AZI had been added, there was a significant increase in the FEV1 (+18.3%+/-14.6%, P <0.0001, analysis of variance) with an absolute increase of 328+/-305 mL. This increase persisted in three patients during 9 months of follow-up.
Conclusions:
AZI is a promising drug for some patients with BOS after lung transplantation. The exact mechanism of action is unknown at the present time.
Related Concept Videos
COPD: Management Using Bronchodilators and Corticosteroids
Asthma-IV: Nursing Management
First, in...
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Pneumothorax-II
Clinical Manifestations:
